Vascular disease in progressive systemic sclerosis (scleroderma).
about
Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associationsUltrastructure of the microvasculature in skin affected by systemic scleroderma.Transcutaneous oxygen pressure in systemic sclerosis: evaluation at different sensor temperatures and relationship to skin perfusion.Blood hyperviscosity with reduced skin blood flow in scleroderma.Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine.Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosisDefective Epstein-Barr virus specific suppressor T cell function in progressive systemic sclerosis.Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma.Large vessel occlusive disease associated with CREST syndrome and sclerodermaPulmonary hypertension in systemic sclerosisAntivascular antibodyInvolvement of the eye in SLE and scleroderma. A study using fluorescein angiography in addition to clinical ophthalmic assessmentIncreased prevalence of symptomatic macrovascular disease in systemic sclerosisIntravital microscopy and capillaroscopically guided nail fold biopsy in scleroderma.Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis.Scleroderma lung diseaseThe post-occlusive hyperemic response in patients with systemic sclerosis.Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosisDistribution of macrovascular disease in sclerodermaVascular involvement in systemic sclerosis (scleroderma).Pathogenesis of Systemic Sclerosis.Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management.Immunopathology of the renal vascular lesion of progressive systemic sclerosis (scleroderma).Chronic cutaneous graft-versus-host disease in man.Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis.Endothelial injury in sclerodermaPulmonary renal syndromes--a review.Vascular disease in scleroderma.Fine structure of digital vascular lesions in Raynaud's phenomenon and disease.Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss.Pathogenesis of progressive systemic sclerosis.Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis.Systemic scleroderma: A review of organ systems.Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene.Interaction of immune and connective tissue cells.The vascular endothelium in scleroderma.Outcomes of sympathectomy and vascular bypass for digital ischaemia in connective tissue disorders.Anti-endothelial cell antibodies: a need for standardization.Central retinal vein occlusion and scleroderma: implications for sclerodermatous vascular disease.
P2860
Q24678420-4AA0D63E-A4EC-43E8-B021-EA56D81B9003Q30844677-699836CA-7A8F-45A3-B2ED-131AB5899C9FQ33419284-13216858-CA92-4CAF-AAC0-A130E81CE0BFQ33551279-ECBF9C6E-57B2-4DA4-ABC7-3EC57AA7ED92Q33551996-500E602E-EAA9-4EAD-8DE3-F98CE120B067Q33553019-F1E6B5AF-3795-458D-99BB-2FE558FAD984Q33556770-D3DD38D9-6736-41F8-BB64-DBAEE486B51DQ33556913-5E44C2F4-DF99-4E23-885F-868F334C3815Q33565537-7F7D515A-22B4-4A0A-AB58-5BAD4ACF0906Q33567883-7E4293ED-15C1-4C29-ADF5-4DA900815571Q33569071-436DFE5F-0594-4B07-B0E0-ACB425279AA1Q33569964-95F7E7DB-7EE3-4770-8034-0C6FDD03EBA9Q33578449-E047B82F-A903-45C5-9F38-7DF6C07F9D85Q33578914-04D532C0-AF03-4F70-BEE7-8FF8098A4BDCQ33579356-E04CF5E7-914D-46A8-BFB4-9D1A6A80EDEEQ33919119-0AD86C80-7C8F-4DBC-AE38-776B88FA91C6Q34196920-CADF2E12-3265-4423-A69C-E995B2AB74B8Q34766502-BB0D922F-9643-4BD2-8C73-FBE9FF061679Q35548113-E164D1F3-0105-4E91-AEE2-46446F35A7C8Q35557424-0501FFCB-72D6-4E66-BA3F-06C5F6CAE59CQ35693212-EF61B8FE-F047-4529-BD77-D3696E857316Q36013674-EF35E129-8C1A-4672-B5B0-F730B17E76BCQ36058517-CD6F7EC7-1C99-45A7-8DB9-455216EFEF79Q36058770-021CA329-FE26-4707-9FC2-D4974AC4B474Q36182730-4B7A5378-4C8B-40EC-A70D-5B67BCE8FEA9Q36341537-17CD9949-267C-4D2A-B016-793CFE6AE772Q36999306-74BEE116-906D-464B-BFCC-FDC7782F6C8EQ37344793-AC0F4490-5101-4C76-A556-3991AD104FF4Q39208866-E15AF04F-82A6-4634-A5DB-FB1E1BB033CEQ39343520-84E0E242-8E84-4662-913E-AA55C642B9A5Q39608534-920963B1-B0BC-464E-A013-E4A4580FE71FQ39736790-A8E92579-F6E5-41E9-BFB7-5D67BAAB4F5BQ39822565-755230C8-ADC9-48BE-B921-A4E1F9C229EDQ39948484-EF596F0A-3190-4804-AE71-003832AD067FQ39982002-AEC2404F-61F7-4535-AC26-5BD096878698Q40293144-F0942980-7A74-4392-9DDA-041A09B58B8CQ40468545-10B3E35E-67C6-4456-9E34-B5C391022868Q40486294-7DEBB8DD-0449-4EE0-A2D6-16B0AFDEC604Q40628388-10FB1ED6-7823-4CE2-97EB-1740DB979EB3Q41122085-AE995405-BC09-44A8-A870-84908EA895F9
P2860
Vascular disease in progressive systemic sclerosis (scleroderma).
description
1970 nî lūn-bûn
@nan
1970年の論文
@ja
1970年学术文章
@wuu
1970年学术文章
@zh-cn
1970年学术文章
@zh-hans
1970年学术文章
@zh-my
1970年学术文章
@zh-sg
1970年學術文章
@yue
1970年學術文章
@zh
1970年學術文章
@zh-hant
name
Vascular disease in progressive systemic sclerosis (scleroderma).
@en
Vascular disease in progressive systemic sclerosis
@nl
type
label
Vascular disease in progressive systemic sclerosis (scleroderma).
@en
Vascular disease in progressive systemic sclerosis
@nl
prefLabel
Vascular disease in progressive systemic sclerosis (scleroderma).
@en
Vascular disease in progressive systemic sclerosis
@nl
P1476
Vascular disease in progressive systemic sclerosis (scleroderma).
@en
P2093
P304
P356
10.7326/0003-4819-73-2-317
P407
P577
1970-08-01T00:00:00Z